Mast Therapeutics, Inc. (NASDAQ:SVRA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating. Mast Therapeutics’ rating score has improved by 50% from 90 days ago as a result of various analysts’ ratings changes.

Analysts have set a 12-month consensus target price of $23.75 for the company and are predicting that the company will post ($0.40) EPS for the current quarter, according to Zacks. Zacks has also assigned Mast Therapeutics an industry rank of 119 out of 265 based on the ratings given to its competitors.

SVRA has been the subject of a number of research reports. JMP Securities initiated coverage on shares of Mast Therapeutics in a report on Monday, September 11th. They issued an “outperform” rating and a $20.00 target price for the company. Roth Capital reduced their target price on shares of Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday. Canaccord Genuity upped their target price on shares of Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 30th. Zacks Investment Research cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 7th. Finally, Jefferies Group LLC initiated coverage on shares of Mast Therapeutics in a report on Friday, September 22nd. They issued a “buy” rating and a $20.00 target price for the company.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at

Mast Therapeutics (SVRA) opened at $9.42 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.83 and a current ratio of 7.83.

In other Mast Therapeutics news, Director Yuri Pikover purchased 50,000 shares of the stock in a transaction dated Friday, October 27th. The shares were acquired at an average cost of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the transaction, the director now directly owns 150,000 shares of the company’s stock, valued at $1,177,500. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.93% of the company’s stock.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Get a free copy of the Zacks research report on Mast Therapeutics (SVRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with's FREE daily email newsletter.